🧠Upcoming NIH Meetings on Grant Applications for Neurological Research
The National Institutes of Health announces closed meetings for the National Institute of Neurological Disorders and Stroke to review grant applications. These virtual meetings are aimed at evaluating funding for clinical trials and research initiatives, ensuring confidentiality of sensitive information associated with grant proposals.
Learn More🧬Notice of Grant Opportunities from the National Human Genome Research Institute
The Department of Health and Human Services announces closed meetings of the National Human Genome Research Institute’s panels to review grant applications. Meetings will focus on evaluating the proposals, including potential commercial implications and ethical considerations, aimed at advancing genome research. The sessions will be held virtually, ensuring accessibility for all involved stakeholders.
Learn More🧬NIH Notice
The Department of Health and Human Services announces a closed meeting of the National Human Genome Research Institute to review grant applications. Attending members will evaluate submissions that may include confidential information, impacting future funding opportunities in the field of genome research and biotechnology.
Learn More🧬NIH Notice of Closed Meeting on Grant Applications
The National Institute of Allergy and Infectious Diseases has announced a closed meeting to evaluate grant applications related to immunobiology and xenotransplantation. The meeting, scheduled for April 2025, will discuss confidential information to ensure the protection of trade secrets and personal data associated with the applications.
Learn More💰NIH Closed Meetings
The Department of Health and Human Services announces closed meetings by the National Institutes of Health to review grant applications for various scientific study sections. These meetings intend to focus on evaluating proposals that may involve confidential trade secrets and personal information. The meetings will be conducted virtually and are closed to the public.
Learn More🚀DOJ Notice on Membership Changes in Rapid Response Partnership Vehicle
The Department of Justice's notice announces changes in the membership of the Rapid Response Partnership Vehicle (RRPV) under the National Cooperative Research and Production Act. New members have been added, while one has withdrawn. The notice emphasizes that no other changes in the group's activities or membership status were made, and future notifications are anticipated.
Learn More⚖️USITC Investigation 337-TA-1352 on Trade Secrets in Pharma
Notice is hereby given that the U.S. International Trade Commission ("Commission") has determined to review a final initial determination ("FID") issued by the presiding Chief Administrative Law Judge ("Chief ALJ"), finding a violation of section 337 of the Tariff Act of 1930, as amended. The Commission requests written submissions from the parties, interested government agencies, and other interested persons on the issues of remedy, the public interest, and bonding, under the schedule set forth below.
Learn More🧬FDA Workshop on Cell Therapies
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public workshop entitled "Cell Therapies and Tissue-Based Products: A Public Workshop on Generating Scientific Evidence to Facilitate Development." The purpose of this workshop is to discuss the current state of the science for development and testing of certain cellular therapies and tissue-based products. In particular, FDA is convening this public workshop with relevant stakeholders to discuss best practices on generating scientific data necessary to further facilitate the development of cellular therapies, including stem cell products.
Learn More⚖️New Export Controls on Biotechnology Equipment for Businesses
With this interim final rule (IFR), the Bureau of Industry and Security (BIS) is revising the Export Administration Regulations (EAR) to address the accelerating development and deployment of advanced biotechnology tools contrary to U.S. national security and foreign policy interests. This rule institutes new controls on certain biotechnology equipment and related technology. It further solicits public comments on the changes it implements.
Learn More🐾FDA Guidance on Type VII Veterinary Master Files for R&D Released
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry (GFI) #260 entitled "Type VII Veterinary Master File for Research and Development and Risk Reviews." This draft guidance, when finalized, will describe FDA's current thinking regarding the use of Type VII Veterinary Master Files (Type VII VMFs). Type VII VMFs are appropriate for research and development of animal cells, tissues, and cell- and tissue-based products (ACTPs), gene therapies, and heritable intentional genomic alterations (IGAs) in animals.
Learn More